Edit

Agenus Inc. ($AGEN)

http://www.agenusbio.com/

Last activity: 13.07.2026

Active

Categories: BioTechHealthcareImmunotherapyOncologyPharma

Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.
For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Follow @Agenus_Bio on Twitter to stay up to date! https://twitter.com/Agenus_Bio

Likes

Followers

2.34K

Website visits

10.9K /mo.

Mentions

Location: United States

Employees: 201-500

Phone: +1 781-674-4200

Total raised: $200M

Founded date: 1994

Investors 3

Date	Name	Website
14.05.2021	EW Healthc...	ewhealthca...
-	Advent Lif...	adventls.c...
-	UVA Licens...	lvg.virgin...

Funding Rounds 1

Date	Series	Amount	Investors
06.07.2021	-	$200M	-

Mentions in press and media 21

Date	Title	Description
13.07.2026	Agenus Announces Up To $340 Million Private Placement To Advance ROBBIN Trial	Agenus announced that it entered into a securities purchase agreement for an oversubscribed private placement of approximately $85 million in upfront gross proceeds and up to an additional $255 million if purchase warrants are fully exercis...
13.05.2026	Zydus to acquire US cancer drug company Assertio for $166.4 million in all-cash deal	Zydus Lifesciences announced on Wednesday that it had signed an agreement via its subsidiary to acquire Assertio Holdings Inc. for $166.4 million in an all-cash deal. Assertio is a Nasdaq-listed pharmaceutical company focused on specialty a...
10.03.2026	C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology	C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications. Through its coll...
10.03.2026	Agenus: $20 Million Triggered Under Zydus Life Sciences Collaboration To Support BOT And BAL Manufacturing	Agenus announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Life Sciences to support manufacturing activities for its lead immuno-oncology programs botens...
03.06.2025	Agenus Receives Investment from Zynext Ventures	Agenus, a Lexington, MA-based immuno-oncology company developing new therapeutics for high-unmet need cancers, received an investment from Zynext Ventures. The amount of the deal was not disclosed. Led by CEO Dr. Garo Armen, Agenus develops...
03.06.2025	Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy	-
13.09.2024	GSK shingles vaccine now available in Malaysia	A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch ...
12.09.2024	AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit	NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July...
16.05.2024	HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]	Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and...
13.03.2023	Agenus Cancels Conference Call to Discuss the Company's Minority Cash Holdings at SVB in Light of Government's SVB Deposit Access Announcement	LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus AGEN, a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its ...
07.03.2022	Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™	Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™ Mon, Mar 07, 2022 13:00 CET Report this content The parties have entered into a collaboration agreement to develop Targovax´s TG mu...
06.07.2021	Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777	LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activa...
28.03.2019	Bristol-Myers Squibb, Concerto HealthAI team up on real-world data, artificial intelligence	Physicians often use the term “real world” to refer to the use of interventions outside the confines of a clinical trial. Real-world data means evidence gathered through routine patient care from sources like electronic health records, medi...
02.01.2016	Agenus Acquires PhosImmune for up to $44.9M	Agenus Inc. (NASDAQ: AGEN), a Lexington, MA-based immunotherapy company developing innovative treatments for cancer, acquired PhosImmune Inc., a Charlottesville, Va.-based company that has discovered an entirely new portfolio of cancer neoa...
08.12.2014	Immunotherapy for STI treatment: Agenus CEO on its genital herpes vaccine	The Massachusetts company has been slowly developing immunotherapy treatments for malaria, a number of cancers and herpes – keeping staunchly at it even when it fell out of favor in the ’90s. “Immunotherapy has been snubbed for many, many y...
23.01.2014	Agenus acquires 4-Antibody AG for up to $50 million
05.03.2012	GSK adds vaccine candidate to AGEN pact, gets first right to buy the firm	If GSK can commercialize a vaccine in the added undisclosed indication, Agenus will gain additional royalties on that product. In addition to the added vaccine indication, Britain-based GSK gets the first right to negotiate for the purchase...
-	Agenus	“Activating the Power of the Immune System to Defeat Cancer”
-	GSK adds vaccine candidate to AGEN pact, gets first right to buy the firm	GlaxoSmithKline (NYSE:GSK) is adding another vaccine target to its partnership with Agenus (NASDAQ:AGEN) and putting itself first in line to acquire the vaccines company outright. GSK is paying Massachusetts-based Agenus $9 million to amend...
-	Immunotherapy for STI treatment: Agenus CEO on its genital herpes vaccine	Many companies are contending to hit the market first in the race for a genital herpes vaccine. The thread that ties them together? Immunotherapy – the wunderdrug for cancer therapy that’s now showing promise for infectious disease. But it ...
-	Bristol-Myers Squibb, Concerto HealthAI team up on real-world data, artificial intelligence	Real-world data and artificial intelligence will soon become part of Bristol-Myers Squibb’s oncology arsenal, under a partnership with a firm focused on real-world evidence generation in cancers. Boston-based Concerto HealthAI and the New Y...

Agenus Inc. ($AGEN)

Investors 3

Funding Rounds 1

Mentions in press and media 21

Reviews 0